Literature DB >> 32420230

Laser therapy versus intravitreal injection of anti-VEGF agents in monotherapy of ROP: a Meta-analysis.

Shi-Dan Wang1, Guo-Ming Zhang1.   

Abstract

AIM: To compare the efficacy and safety between laser therapy and anti-vascular endothelial growth factor (VEGF) agents intravitreal injection monotherapy in type-1 retinopathy of prematurity (ROP) and aggressive posterior retinopathy of prematurity (APROP).
METHODS: A systematic literature search was performed in PubMed, Cochrane Library, and Embase for original comparable studies. We included studies that compare laser therapy and intravitreal injections of anti-VEGF agents monotherapy in ROP regardless of languages and publication types.
RESULTS: Complication incidence was significantly higher in laser therapy group (OR: 0.38; 95%CI: 0.19-0.75; P=0.005). Spherical equivalent (SE) was higher in laser therapy [weighted mean difference (WMD): 2.40, 95%CI: 0.88-3.93; P=0.002]. The time between treatment and retreatment was longer in laser therapy group (WMD: 8.45, 95%CI: 5.35-11.55; P<0.00001). Recurrence incidence (OR: 0.97; 95%CI: 0.45-2.09; P=0.93) and retreatment incidence (OR: 1.24; 95%CI: 0.56-2.73; P=0.59) were similar in two approaches. Subgroup analysis between type-1 ROP and APROP was not significant except SE reported in the included studies (P<0.0001).
CONCLUSION: This Meta-analysis outcome indicates anti-VEGF agents are as effective as laser treatment, and safer than laser in type-1 ROP and APROP. The degree of myopia in APROP is higher than type-1 ROP. More randomized controlled trials in large sample size should be conducted in the future. International Journal of Ophthalmology Press.

Entities:  

Keywords:  Meta-analysis; anti-vascular endothelial growth factor; bevacizumab; laser therapy; ranibizumab; recurrence; retinopathy of prematurity

Year:  2020        PMID: 32420230      PMCID: PMC7201341          DOI: 10.18240/ijo.2020.05.17

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  36 in total

Review 1.  Extended lymphadenectomy versus conventional surgery for rectal cancer: a meta-analysis.

Authors:  Panagiotis Georgiou; Emile Tan; Nikolaos Gouvas; Anthony Antoniou; Gina Brown; R John Nicholls; Paris Tekkis
Journal:  Lancet Oncol       Date:  2009-09-18       Impact factor: 41.316

2.  Quantitative synthesis in systematic reviews.

Authors:  J Lau; J P Ioannidis; C H Schmid
Journal:  Ann Intern Med       Date:  1997-11-01       Impact factor: 25.391

3.  Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of Prematurity in Turkish Preterm Children.

Authors:  Emrah Utku Kabataş; Bengi Ece Kurtul; Pınar Altıaylık Özer; Naciye Kabataş
Journal:  Curr Eye Res       Date:  2017-01-27       Impact factor: 2.424

Review 4.  [Retinopathy of prematurity].

Authors:  V Promelle; S Milazzo
Journal:  J Fr Ophtalmol       Date:  2017-04-03       Impact factor: 0.818

5.  Retrospective cohort study shows that the risks for retinopathy of prematurity included birth age and weight, medical conditions and treatment.

Authors:  Aliaa A Ali; Nancy A S Gomaa; Ahmed R Awadein; Huda H Al-Hayouti; Ahmed I Hegazy
Journal:  Acta Paediatr       Date:  2017-09-18       Impact factor: 2.299

6.  Follow-up to Age 4 Years of Treatment of Type 1 Retinopathy of Prematurity Intravitreal Bevacizumab Injection versus Laser: Fluorescein Angiographic Findings.

Authors:  Domenico Lepore; Graham E Quinn; Fernando Molle; Lorenzo Orazi; Antonio Baldascino; Marco H Ji; Maria Sammartino; Fabio Sbaraglia; Daniela Ricci; Eugenio Mercuri
Journal:  Ophthalmology       Date:  2017-09-01       Impact factor: 12.079

7.  Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial.

Authors:  Megan M Geloneck; Alice Z Chuang; W Lloyd Clark; Michael G Hunt; Alan A Norman; Eric A Packwood; Khaled A Tawansy; Helen A Mintz-Hittner
Journal:  JAMA Ophthalmol       Date:  2014-11       Impact factor: 7.389

8.  Low-dose ranibizumab as primary treatment of posterior type I retinopathy of prematurity.

Authors:  Anna L Ells; Jason D Wesolosky; April D Ingram; Patrick C Mitchell; Alexander S Platt
Journal:  Can J Ophthalmol       Date:  2017-07-19       Impact factor: 1.882

Review 9.  Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.

Authors:  Mari Jeeva Sankar; Jhuma Sankar; Parijat Chandra
Journal:  Cochrane Database Syst Rev       Date:  2018-01-08

10.  Regression Rates Following the Treatment of Aggressive Posterior Retinopathy of Prematurity with Bevacizumab Versus Laser: 8-Year Retrospective Analysis.

Authors:  Simona D Nicoară; Anne C Ștefănuţ; Constanta Nascutzy; Gabriela C Zaharie; Laura E Toader; Tudor C Drugan
Journal:  Med Sci Monit       Date:  2016-04-10
View more
  5 in total

1.  Refractive status, biometric components, and functional outcomes of patients with threshold retinopathy of prematurity: systemic review and a 17-year longitudinal study.

Authors:  Yu-Bai Chou; An-Guor Wang; Hsin-Yu Yang; Kuan-Jung Chen; Chang-Sue Yang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-06-22       Impact factor: 3.117

2.  A systematic review and meta-analysis of preanalytical factors and methodological differences influencing the measurement of circulating vascular endothelial growth factor.

Authors:  Ulrika Sjöbom; Anders K Nilsson; Hanna Gyllensten; Ann Hellström; Chatarina Löfqvist
Journal:  PLoS One       Date:  2022-07-06       Impact factor: 3.752

3.  Clinical outcome following reinjection of Ranibizumab for reactivation of retinopathy of prematurity.

Authors:  Rania M Bassiouny; Walid M Gaafar; Amgad El Nokrashy; Ameera G Abdelhameed; Eman A Attallah; Ahmed G Elgharieb; Mohamed R Bassiouny
Journal:  Eye (Lond)       Date:  2021-10-28       Impact factor: 4.456

4.  Cytochrome P450 2J2 inhibits the proliferation and angiogenesis of retinal vascular endothelial cells by regulating the Notch signaling pathway in a hypoxia-induced retinopathy model.

Authors:  Jing Zhang; Qi Xiong; Lin Yang; Yanni Xue; Min Ke; Zhi Li
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

Review 5.  New Aspects on the Treatment of Retinopathy of Prematurity: Currently Available Therapies and Emerging Novel Therapeutics.

Authors:  Juhee Ryu
Journal:  Int J Mol Sci       Date:  2022-08-01       Impact factor: 6.208

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.